The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Clinical decision tool for guiding outpatient vs inpatient bispecific antibody therapy in myeloma
Shahzad Raza, MD, Cleveland Clinic, Cleveland, OH, shares insight into a clinical decision tool to guide outpatient versus inpatient bispecific antibody therapy in patients with multiple myeloma, highlighting the use of artificial intelligence tools to predict therapy-related complications. Dr Raza explains that a scoring system can assess various factors and guide clinicians in deciding which patients can be safely managed as outpatients and which require hospitalization. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
